Raman Prakash reported grant involving 6,801 shares of Black Diamond Therapeutics, Inc. at $1.93 for $13.1k on Sep 18, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$13,125.93Shares × reported price
Shares traded
6,801Common Stock
Price per share
$1.93Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
51,840Direct
Trade date
Sep 18, 2026Grant
Filed
Sep 21, 2026, 5:30 PM ET3-day reporting delay
Accession
0002018686-26-000014Code A · Transaction 226962
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

BDTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BDTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Sep 28, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.